Helaina Raises $45 Million in Series B Funding to Accelerate the Commercialization of Human Bioactive Proteins Starting with effera™ Human Lactoferrin

NEW YORK–(BUSINESS WIRE)–Helaina, the biotechnology company transforming nutrition with human equivalent bioactive proteins, announced today it has raised $45 million in Series B funding, bringing the company’s total equity funding to $83 million. The round was led by Avidity Partners, with additional investment from Spark Capital, Ingeborg Investments, Tom Williams of Heron Rock, Barrel Ventures, Siam Capital, Relish Works, CF Private Equity and Primary Venture Partners, among other strategi